Compare
AbbVie vs Henry Schein (ABBV vs HSIC)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Henry Schein (HSIC) +19.5%; so far this year the figures are +27.5% and +13.8%.
AbbVie is the larger company by market value, about 54.1 times the size of Henry Schein.
On trailing earnings, ABBV trades at 50.1 times and HSIC at 23.6 times.
Revenue grew +10.7% at ABBV and +6.2% at HSIC over the last year.
ABBV yields 2.38%. HSIC pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | HSIC | |
|---|---|---|
| Price | $291.31 | $86.05 |
| 1-day | +1.07% | +0.87% |
| YTD | +27.49% | +13.85% |
| 1 year | +34.39% | +19.50% |
| 3 years | +104.47% | +34.31% |
| Market cap | $514.9B | $9.5B |
| P/E | 50.1 | 23.6 |
| P/S | 7.80 | 0.69 |
| P/B | — | 3.01 |
| Revenue growth | +10.70% | +6.20% |
| EPS growth | +340.20% | +15.10% |
| Gross margin % | 73.7 | 31.6 |
| Net margin % | 15.7 | 3.1 |
| ROE % | — | 13.3 |
| Debt / equity | — | 1.07 |
| FCF yield % | 3.7 | 5.9 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.62 |
| RSI (14) | 59.7 | 51.3 |
| Technical rating |